Clinical-stage biotech firm Kailera Therapeutics has successfully priced its initial public offering at the top of its range. The offering represents the largest US listing in the obesity treatment sector since 2021.
- Raised $625 million via upsized IPO
- Shares priced at $16, the top of the $14-$16 range
- Sold 39 million shares, exceeding the initial 33.3 million offer
- Largest US listing in the obesity sector since 2021
- Offering was double-digits oversubscribed
Sign up free to read the full analysis
Create a free account to unlock full AI-curated market articles, personalized alerts, and more.